Amicus Therap Us patents expiration
1. Galafold patents expiration
GALAFOLD's oppositions filed in EPO
Can you believe GALAFOLD received compensation for the extended wait time during the regulatory approval process?
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11357765 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11304940 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11612594 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11357764 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11376244 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11612593 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11426396 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11633387 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11786516 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11826360 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
Feb, 2039
(14 years from now) | |
| US11622962 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
Mar, 2039
(14 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10406143 | AMICUS THERAP US | Methods for treatment of fabry disease |
May, 2027
(3 years from now) | |
| US10383864 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(3 years from now) | |
| US11241422 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(3 years from now) | |
| US9000011 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(3 years from now) | |
| US9480682 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(3 years from now) | |
| US9987263 | AMICUS THERAP US | Methods for treatment of Fabry disease |
May, 2027
(3 years from now) | |
| US10525045 | AMICUS THERAP US | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
Apr, 2028
(4 years from now) | |
| US9999618 | AMICUS THERAP US | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
Apr, 2028
(4 years from now) | |
| US10925866 | AMICUS THERAP US | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
Apr, 2028
(4 years from now) | |
| US11033538 | AMICUS THERAP US | Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones |
Apr, 2028
(4 years from now) | |
| US9095584 | AMICUS THERAP US | Method to predict response to pharmacological chaperone treatment of diseases |
Feb, 2029
(4 years from now) | |
| US10813921 | AMICUS THERAP US | Method to predict response to pharmacological chaperone treatment of diseases |
Feb, 2029
(4 years from now) | |
| USRE48608 | AMICUS THERAP US | Method to predict response to pharmacological chaperone treatment of diseases |
Feb, 2029
(4 years from now) | |
| US8592362 | AMICUS THERAP US | Method to predict response to pharmacological chaperone treatment of diseases |
Feb, 2029
(4 years from now) | |
| US10076514 | AMICUS THERAP US | Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene |
Mar, 2037
(12 years from now) | |
| US11234972 | AMICUS THERAP US | Methods of treating fabry disease in patients having the G9331A mutation in the GLA gene |
Mar, 2037
(12 years from now) | |
| US10792278 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US10849889 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US10857142 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US10471053 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US10874655 | AMICUS THERAP US | Methods of treating fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US10874657 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11666564 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US10792279 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11813255 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US10874656 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US10849890 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11389437 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US10857141 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11357761 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US10799491 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US10806727 | AMICUS THERAP US | Methods of treating fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11278540 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11278536 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11278537 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11278538 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11458128 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11357763 | AMICUS THERAP US | Methods of treating fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11278539 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11389436 | AMICUS THERAP US | Methods of treating fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11357762 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US10251873 | AMICUS THERAP US | Methods of treating fabry patients having renal impairment |
May, 2038
(14 years from now) | |
| US11357784 | AMICUS THERAP US | Use of migalastat for treating Fabry disease in pregnant patients |
Feb, 2039
(14 years from now) | |
| US11642334 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
Feb, 2039
(14 years from now) | |
| US11633388 | AMICUS THERAP US | Methods of treating Fabry patients having renal impairment |
Mar, 2039
(14 years from now) | |
| US11833164 | AMICUS THERAP US | Methods of treating Fabry disease in patients having a mutation in the GLA gene |
Jan, 2042
(17 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-205) | Aug 10, 2025 |
| New Chemical Entity Exclusivity(NCE) | Aug 10, 2023 |
Drugs and Companies using MIGALASTAT HYDROCHLORIDE ingredient
NCE-1 date: 10 August, 2022
Market Authorisation Date: 10 August, 2018
Treatment: The treatment of fabry patients; A method of reducing left ventricular mass index (lvmi) in a fabry patient by administering migalastat
Dosage: CAPSULE;ORAL
How can I launch a generic of GALAFOLD before it's drug patent expiration?
More Information on Dosage
GALAFOLD family patents
2. Opfolda patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10208299 | AMICUS THERAP US | Highly potent acid alpha-glucosidase with enhanced carbohydrates |
Sep, 2035
(11 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11278599 | AMICUS THERAP US | High concentration alpha-glucosidase compositions for the treatment of Pompe disease |
Mar, 2033
(8 years from now) | |
| US10512677 | AMICUS THERAP US | High concentration alpha-glucosidase compositions for the treatment of pompe disease |
Mar, 2033
(8 years from now) | |
| US10961522 | AMICUS THERAP US | Highly potent acid alpha-glucosidase with enhanced carbohydrates |
Sep, 2035
(11 years from now) | |
| US11753632 | AMICUS THERAP US | Highly potent acid alpha-glucosidase with enhanced carbohydrates |
Sep, 2035
(11 years from now) | |
| US11278601 | AMICUS THERAP US | Augmented acid alpha-glucosidase for the treatment of Pompe disease |
Dec, 2036
(12 years from now) | |
| US10857212 | AMICUS THERAP US | Augmented acid alpha-glucosidase for the treatment of Pompe disease |
Aug, 2037
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Sep 28, 2026 |
Drugs and Companies using MIGLUSTAT ingredient
Market Authorisation Date: 28 September, 2023
Treatment: The treatment of pompe patients
Dosage: CAPSULE;ORAL
More Information on Dosage
OPFOLDA family patents